|
(V49) |
Spironolactone reduces intracellular Na+ concentration in cardiac myocytes of mice after myocardial infarction |
| |
|
F. Dithmar, T. Weinaus, M. Kohlhaas, F. Gutjahr, I. Elabyad, C. Maack, W. R. Bauer, M. Christa (Würzburg) |
|
|
Diskussion |
|
(V50) |
PhospholambanR9C mutation disturbs Ca2+ handling with consequences for excitation/contraction coupling but also for mitochondria and the ER |
| |
|
T. Brand, T. Baumgarten, S. Denzinger, Y. Reinders, M. Kleindl, F. Funk, N. Gedik, P. Kleinbongard, E. Tolstik, A. Sickmann, J. Schmitt, K. Lorenz (Würzburg, Dortmund, Düsseldorf, Essen) |
|
|
Diskussion |
|
(V51) |
Role of Transmembrane Bax Inhibitor motif -containing protein 5 (TMBIM5) on cytosolic and mitochondrial Ca2+ handling and redox regulation |
| |
|
A.-F. Schiuma, F. Dietsche, M. Kohlhaas, A. Nickel, C. Maack, A. Methner (Würzburg, Mainz) |
|
|
Diskussion |
|
(V52) |
Disturbed cardiac Ca2+ handling and endothelial dysfunction contribute to RBM20 mutation-based left ventricular non-compaction cardiomyopathy |
| |
|
S. Rebs, T. A. Buchwald, F. Sedaghat-Hamedani, E. Kayvanpour, A. Wagdi, G. Hasenfuß, B. Meder, K. Streckfuß-Bömeke (Würzburg, Göttingen, Heidelberg) |
|
|
Diskussion |
|
(V53) |
Relaxin family peptide Receptor 1 (RXFP1) for heart failure gene therapy |
| |
|
P. Schlegel, N. Sasipong, J. Wingert, E. Meinhardt, P. Most, H. A. Katus, N. Frey, P. Raake (Heidelberg) |
|
|
Diskussion |
|
(V54) |
Empagliflozin does not reduce intracellular Na+ in cardiac myocytes of mice with pressure overload induced heart failure |
| |
|
T. Weinaus, F. Dithmar, M. Kohlhaas, F. Gutjahr, C. Maack, W. R. Bauer, M. Christa (Würzburg) |
|
|
Diskussion |